• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sidoti's November Micro-Cap Virtual Conference

    11/8/22 3:40:00 PM ET
    $CGRN
    $DPSI
    $FGI
    $GIFI
    Industrial Machinery/Components
    Industrials
    Computer Software: Programming Data Processing
    Technology
    Get the next $CGRN alert in real time by email
    • Presentation Times and Weblinks Released for Over 35 Presenting Companies
    • Wednesday and Thursday, November 9-10, 2022

    NEW YORK, NY / ACCESSWIRE / November 8, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November 9-10, 2022. The links can also be found at www.sidoticonference.com/events .

    Sidoti & Company, LLC, Tuesday, November 8, 2022, Press release picture

    Presentation Agenda

    Wednesday, November 9th, 2022 (Day 1)

    9:15-9:45

    Bel Fuse (BELFB)

    Splash Beverage Group (SBEV)

    Generation Income Properties (GIPR)

    10:00-10:30

    *****

    Miromatrix Medical Inc. (MIRO)

    FRX Innovations (FRXI)

    10:45-11:15

    Guerrilla RF (GUER)

    CVG (CVGI)

    EzFill Holdings (EZFL)

    11:30-12:00

    CareCloud (MTBC)

    Mistras Group (MG)

    *****

    12:15-12:45

    Civeo Corporation (CVEO)

    XORTX Therapeutics, Inc. (XRTX)

    Mill City Ventures III (MCVT)

    1:00-1:30

    *****

    Blue Star Foods (BSFC)

    Argentina Lithium & Energy (PNXLF)

    1:45-2:15

    *****

    Akari Therapeutics (AKTX)

    Conifex Timber Inc. (CFF)

    2:30-3:00

    Ascent Industries Co. (ACNT)

    Transcode (RNAZ)

    Ashford Hospitality Trust (AHT)

    3:15-3:45

    Heartcore Enterprises, Inc. (HTCR)

    Electromed, Inc. (ELMD)

    *****

    4:00-4:30

    ShiftPixy, Inc. (PIXY)

    Propanc Biopharma Inc. (PPCB)

    *****

    1x1s Only

    Quanex Building Products (NX)

    Thursday, November 10th, 2022 (Day 2)

    9:15-9:45

    SmartKem (SMTK)

    TARENA International (TEDU)

    *****

    10:00-10:30

    *****

    Loop Industries (LOOP)

    *****

    10:45-11:15

    TESSCO Technologies (TESS)

    *****

    *****

    11:30-12:00

    DecisionPoint Systems (DPSI)

    *****

    Independence Contract Drilling (ICD)

    12:15-12:45

    Boardwalktech Software (BWLKF)

    HOOKIPA Pharma Inc. (HOOK)

    *****

    1:00-1:30

    SOBR Safe Inc (SOBR)

    MAIA Biotechnology, Inc. (MAIA)

    Capstone Green Energy (CGRN)

    1x1s Only

    FGI Industries (FGI) | Gulf Island Fabrication (GIFI)

    About Sidoti
    For over two decades, Sidoti has been a premier provider of independent securities research focused specifically on Small Cap and Micro-Cap companies and the institutions that invest their securities, with most of our coverage in the $50 million to $3 billion market cap range. Our approach affords companies and institutional clients a combination of high-quality research, a Small Cap and Micro-Cap focused nationwide sales effort, and broad access to corporate management teams. We serve 500+ institutional clients in the U.S. and Canada, including many leading institutional managers. Sidoti promotes meaningful interaction between issuers and investors in the Small Cap and Micro-Cap space through a series of investor conferences ( www.sidoti.com/events ) we host each year.

    CONTACT
    Sidoti Events Team
    212-453-7031
    [email protected]

    SOURCE: Sidoti & Company, LLC



    View source version on accesswire.com:
    https://www.accesswire.com/724582/Sidotis-November-Micro-Cap-Virtual-Conference

    Get the next $CGRN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CGRN
    $DPSI
    $FGI
    $GIFI

    CompanyDatePrice TargetRatingAnalyst
    HOOKIPA Pharma Inc.
    $HOOK
    12/20/2024$48.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    HOOKIPA Pharma Inc.
    $HOOK
    11/15/2024$50.00 → $48.00Outperform
    RBC Capital Mkts
    Gulf Island Fabrication Inc.
    $GIFI
    3/8/2024Hold → Accumulate
    Johnson Rice
    Loop Industries Inc.
    $LOOP
    12/29/2022Buy → Neutral
    H.C. Wainwright
    HOOKIPA Pharma Inc.
    $HOOK
    12/2/2022Neutral → Underperform
    BofA Securities
    Independence Contract Drilling Inc.
    $ICD
    3/22/2022$7.00Hold → Buy
    Johnson Rice
    FGI Industries Ltd.
    $FGI
    2/23/2022$7.00Outperform
    Northland Capital Markets
    HOOKIPA Pharma Inc.
    $HOOK
    2/17/2022$15.00 → $8.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Guerrero Ramiro

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      7/2/25 4:17:45 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chaouki Steven M

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      7/2/25 4:16:50 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Louie Ngar Yee

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      7/2/25 4:16:10 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGRN
    $DPSI
    $FGI
    $GIFI
    SEC Filings

    See more
    • SOBR Safe Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - SOBR Safe, Inc. (0001425627) (Filer)

      7/18/25 5:25:16 PM ET
      $SOBR
      Newspapers/Magazines
      Consumer Discretionary
    • HOOKIPA Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - HOOKIPA Pharma Inc. (0001760542) (Filer)

      7/18/25 4:11:36 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      7/17/25 4:05:38 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Smith Stan bought $50,000 worth of shares (33,333 units at $1.50) (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      6/5/25 4:42:27 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Guerrero Ramiro bought $30,000 worth of shares (20,000 units at $1.50), increasing direct ownership by 4% to 588,218 units (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      5/12/25 4:14:02 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Smith Stan bought $99,999 worth of shares (66,666 units at $1.50) (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      5/12/25 4:12:43 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

      NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA")), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced its intention to voluntarily delist from the Nasdaq Capital Market ("Nasdaq") and to deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and suspend its reporting obligations under Section 15(d) of the Exchange Act. In connection with the consideration and evaluation of HOOKIPA's long-term prospects and strategies by HOOKIPA's board of dire

      7/18/25 4:05:00 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

      MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced dosing of the first patient in Taiwan in the expansion phase of its THIO-101 Phase 2 trial for advanced non-small cell lung cancer (NSCLC). The trial's entry into another continent marks a key milestone for MAIA, opening a significantly larger patient pool for its evaluations of ateganosine (THIO). Screening for the trial is ongoing in Europe and Asia. Trial Design: The expansion study evaluates ateganosine in heavily pre-treated patients in third-line (3L) NSCLC who have previously failed treatment with checkpoint inhibitors (CPIs) an

      7/9/25 9:15:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

      MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced two upcoming poster presentations at the 49th Federation of European Biochemical Societies (FEBS) 2025 Congress, hosted by the Turkish Biochemical Society, to be held July 5-9, 2025, in Istanbul, Turkey. The poster presentations highlight MAIA's lead telomere-targeting agent and next-generation treatments. The first presentation will be delivered by MAIA Scientific Advisory Board member, Z. Gunnur Dikmen, M.D., Ph.D., Hacettepe University, Faculty of Medicine, Department of Biochemistry in Ankara, Turkey. Poster

      7/1/25 9:00:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Leadership Updates

    Live Leadership Updates

    See more
    • MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

      Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

      6/24/25 8:15:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

      Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC)   MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). "We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology," said V

      3/25/25 8:46:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

      Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head and neck cancer Strength of HB-700 KRAS-inhibitor program highlighted by preclinical dataset presented at recent RAS Targeted Drug Development Summit NEW YORK and VIENNA, Austria, Nov. 14, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")

      11/14/24 4:05:00 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HOOKIPA Pharma downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded HOOKIPA Pharma from Outperform to Sector Perform and set a new price target of $2.00 from $48.00 previously

      12/20/24 7:37:05 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target

      RBC Capital Mkts reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $48.00 from $50.00 previously

      11/15/24 11:07:50 AM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gulf Island Fab upgraded by Johnson Rice

      Johnson Rice upgraded Gulf Island Fab from Hold to Accumulate

      3/8/24 11:07:40 AM ET
      $GIFI
      Metal Fabrications
      Industrials

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

      SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

      11/14/24 6:07:08 PM ET
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by MAIA Biotechnology Inc.

      SC 13D/A - MAIA Biotechnology, Inc. (0001878313) (Subject)

      10/25/24 6:16:55 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by MAIA Biotechnology Inc.

      SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

      10/25/24 5:12:55 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Financials

    Live finance-specific insights

    See more
    • Gulf Island Reports First Quarter 2025 Results

      THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Gulf Island Fabrication, Inc. (NASDAQ:GIFI) ("Gulf Island" or the "Company"), a leading steel fabricator and service provider to the industrial and energy sectors, today announced its results for the first quarter 2025. FIRST QUARTER 2025 SUMMARY Consolidated revenue of $40.3 millionConsolidated net income of $3.8 million; Consolidated EBITDA of $4.5 millionServices division operating income of $1.6 million; EBITDA of $2.1 millionFabrication division operating income of $3.8 million; EBITDA of $4.5 millionEntered into agreement in April to acquire certain assets of ENGlobal Corporation ("ENG") relating to its automation, eng

      5/6/25 4:05:56 PM ET
      $GIFI
      Metal Fabrications
      Industrials
    • Gulf Island Announces First Quarter 2025 Results Conference Call Date

      THE WOODLANDS, Texas, April 29, 2025 (GLOBE NEWSWIRE) -- Gulf Island Fabrication, Inc. ("Gulf Island" or the "Company") (NASDAQ:GIFI), a leading steel fabricator and service provider to the industrial and energy sectors, today announced that it will report financial results for the first quarter 2025 after the market close on Tuesday, May 6, 2025. Gulf Island management will hold a conference call on Tuesday, May 6, 2025, at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss the Company's financial results. The call will be available by webcast and can be accessed on Gulf Island's website at http://www.gulfisland.com. Participants may also join the call by calling 1.877.704.4453

      4/29/25 4:05:21 PM ET
      $GIFI
      Metal Fabrications
      Industrials
    • FGI INDUSTRIES ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2024 RESULTS

      EAST HANOVER, N.J., March 26, 2025 /PRNewswire/ -- FGI Industries Ltd. (NASDAQ:FGI) ("FGI" or the "Company"), a leading global supplier of kitchen and bath products, today announced results for the fourth quarter and full-year 2024. FOURTH QUARTER 2024 HIGHLIGHTS(As compared to the fourth quarter of 2023) Total revenue of $35.6 million, +15.0% y/yGross profit of $8.7 million, -3.2% y/yGross margin of 24.6%, -460 bps y/yOperating loss of $1.3 million and net loss attributable to shareholders of $0.4 millionAdjusted operating loss of $1.1 millionAdjusted net loss of $0.7 million

      3/26/25 4:30:00 PM ET
      $FGI
      Industrial Specialties
      Industrials